AIM
TCON

Alambic Investment Management’s TRACON Pharmaceuticals, Inc. Common Stock TCON Stock Holding History

Alambic Investment Management’s Portfolio TCON Stock Details TCON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-228
Closed -$93K – 387
2018
Q3 		$93K Sell
228
-174
-43% -$80.6K 0.07% 250
2018
Q2 		$217K Sell
402
-61
-13% -$32.4K 0.06% 304
2018
Q1 		$213K Buy
+463
New +$253K 0.03% 410

Other funds holding TCON

PCM
Puissance Capital Management New York $17.3M AUM 149.36% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
TI
Telemetry Investments New York $63.3M AUM 0.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Alambic Investment Management's TCON Position: Q4 2018 in Review

Alambic Investment Management sold out of TRACON Pharmaceuticals, Inc. Common Stock (TCON) in Q4 2018, closing a stake of 228 shares — an estimated $93K sold.

Alambic Investment Management first reported a position in TCON in Q1 2018 and held it in 3 quarters. The position peaked at $217K in Q2 2018. 27 funds tracked by Wall St. Rank hold TCON as of Q4 2018.

  • Alambic Investment Management reported no remaining TRACON Pharmaceuticals, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
  • Alambic Investment Management sold 228 TRACON Pharmaceuticals, Inc. Common Stock shares in Q4 2018, an estimated $93K.
  • Alambic Investment Management first reported a position in TRACON Pharmaceuticals, Inc. Common Stock in Q1 2018 and held it in 3 quarters.
  • Alambic Investment Management's TRACON Pharmaceuticals, Inc. Common Stock position peaked at $217K in Q2 2018.
  • 27 funds tracked by Wall St. Rank held TRACON Pharmaceuticals, Inc. Common Stock as of Q4 2018.

Based on Alambic Investment Management's 13F filing for Q4 2018, filed 12 Feb 2019.